Quantcast

Latest Sipuleucel-T Stories

2010-03-03 17:00:00

SEATTLE, March 3 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced updated results from its pivotal Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study demonstrating that PROVENGE® (sipuleucel-T) extends overall survival in men with metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC).

2010-02-22 15:00:00

SEATTLE, Feb. 22 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the year and quarter ended December 31, 2009. Revenue for the year ended December 31, 2009 was $101,000 compared to $111,000 for year ended December 31, 2008.

2009-12-10 18:48:00

SEATTLE, Dec. 10 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced today that it has priced its underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $24.75 per share.

2009-12-10 05:30:00

SEATTLE, Dec. 10 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Hans Bishop has joined the Company as chief operating officer, effective January 4, 2010. Mr.

2009-12-08 16:09:00

SEATTLE, Dec. 8 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced today that it has commenced an underwritten public offering, subject to market and other conditions, of 15,000,000 shares of its common stock pursuant to an effective shelf registration statement.

2009-11-20 07:30:00

SEATTLE, Nov. 20 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response.

2009-11-11 15:00:00

SEATTLE, Nov. 11 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended September 30, 2009. Revenue for the third quarter of 2009 was $25,000 compared to $26,000 for the quarter ended September 30, 2008.

2009-11-02 07:30:00

SEATTLE, Nov. 2 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that it has completed the submission of the amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T), the Company's lead investigational product, to the U.S.


Word of the Day
quilisma
  • In medieval musical notation, a sign or neume denoting a shake or trill.
The word 'quilisma' comes from a Greek word meaning 'a roll'.